MedPath

Clinical evaluation for the efficacy of Muliv strong syrup in the management of Non- Alcoholic Fatty Liver disease (NAFLD).

Phase 2
Conditions
Other specified inflammatory liverdiseases,
Registration Number
CTRI/2019/12/022578
Lead Sponsor
Multani Pharmaceuticals Ltd
Brief Summary

It is an open labeled single armed, single centric, prospective interventional clinical study to evaluate the efficacy of Muliv Strong Syrup on 50 patients suffering Non- Alcoholic Fatty Liver disease (NAFLD). The study will be conducted in National Institute of Ayurveda, Jaipur, Rajasthan,

Dose: 10 ml tds Muliv Strong Syrup orally will be given before meal with luke warm water for 45days.

**Purpose** –

To evaluate the effect of Muliv Strong Syrup in the management of Non- Alcoholic Steatohepatitis (NASH).

 **Research question:** Is Muliv Strong Syrup is effective in management of Non- Alcoholic Fatty Liver disease (NAFLD).

**Null Hypothesis**: Muliv Strong Syrup is not effective in the management of Non- Alcoholic Fatty Liver disease (NAFLD).

**Alternative hypothesis**: Muliv Strong Syrup is effective in the management of Non- Alcoholic Fatty Liver disease (NAFLD).

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients of either sex not taking any medicine will be included in the study.
  • Individuals suffering from NAFLD with or without elevated liver enzymes or hepatomegaly will be included.
  • Patients willing to give informed consent for the study.
Exclusion Criteria
  • Individuals with chronic hepatitis (more than 3 months), Patients with malignant jaundice, patient with acute hepatitis (Other than infective).
  • Individuals with known hypersensitivity to ingredients of study products; individuals with immediate life threatening diseases such as preexisting cardiovascular, liver, or neoplastic diseases or who received any immunosuppressant, sedative, hypnotic or tranquilizer within 14 days prior to enrollment; 3.
  • Individuals with any psychiatric illness which may impair the ability to provide written ICF.
  • Individuals participating in any other clinical trial.
  • Pregnant or lactating females.
  • Alcohol, smoke, and drug abusers will be excluded from study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in NAFLD Score60 days
Secondary Outcome Measures
NameTimeMethod
Changes in Subjective parameters, LFT, USG60days

Trial Locations

Locations (1)

National Institute of Ayurveda

🇮🇳

Jaipur, RAJASTHAN, India

National Institute of Ayurveda
🇮🇳Jaipur, RAJASTHAN, India
Dr Gopesh Mangal
Principal investigator
8619849011
gmangal108@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.